



10 March 2022

Dear members of SMA Europe,

Over the past few days, Roche has been working diligently to better understand the rapidly evolving situation in Ukraine and the impact on the SMA community. As the conflicts continue, we recognize the significant challenges faced by people living with SMA and their families and the urgent need to help those affected by the crisis.

As part of our ongoing partnership and following your request to receive important and timely updates, we want to provide you with a summary of our immediate response measures. Roche is committed to ensuring that our critical medicines and diagnostics reach the people who need them both in Ukraine and other countries impacted by the crisis. Our teams are closely monitoring the changing situation and working to adapt as quickly as possible.

Maintaining risdiplam supply

Ukraine

Our primary focus is ensuring continued supply of risdiplam within the scope of the available possibilities. While borders are not officially closed, it is extremely difficult to get any shipments into the country. Currently we have sufficient product supply in Ukraine but are hindered by the severe destruction of local infrastructure, and disruption to logistics and supply chain channels. We are making every effort to ensure our medicines reach centres that remain able to provide care and are seeking alternative means of distribution for individual patients where this is not the case.

Russia

The supply and delivery of medicines and diagnostics are currently exempted from sanctions. We are doing everything we can to maintain supply and delivery within the scope of the available possibilities.

Risdiplam support programme for Ukraine

Roche has initiated a global support programme to ensure uninterrupted access to treatment for all patients in or from Ukraine who are currently receiving risdiplam. This includes patients that are receiving risdiplam through our clinical trials, the Pre-Approval Access/Compassionate Use (PAA/CU) Programme or other commercial pathways (i.e., out of pocket purchase or state funded programme in Ukraine). The programme supports patients who are currently in Ukraine or those who have left the country due to the unrest.

To address questions from affected patients/caregivers, Roche has launched a dedicated, interpreter-assisted patient hotline offering 24/7 information and individualised support. The hotline can be reached via email at firefish.psp@roche.com or phone +41 79 899 9267 (may be subject to local carrier fees). Please direct all patient queries to the Roche hotline.

During these unprecedented times, Roche remains committed to supporting the SMA community and those affected in Ukraine. We thank you for your ongoing partnership and tremendous efforts during this extraordinary time.

If you/your members have any questions about this update, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink that reads "Fani Petridis".

Fani Petridis, on behalf of the Roche Global SMA Team
Senior Director, Global Patient Partnership - Rare Diseases (SMA)